In enzyme inhibitor design, the carbamate group plays a crucial role by carbamoylating the enzyme's active site, prolonging its inhibitory effect and enhancing therapeutic efficacy.19 This has been demonstrated in drugs such as rivastigmine, an AChE inhibitor containing a carbamate moiety, and JZL-184, a MAGL inhibitor with a similar structure.20,21 The incorporation of the carbamate group in AChE and MAGL inhibitor design may open new avenues for AD treatment. Here, MGLL is linked to Alzheimer disease.